3-methoxy-6-{2-[(3-{[2-(3-methoxy-9-methyl-7-oxo-7H-5,10-diaza-benzo[c]fluoren-6-ylamino)-ethyl]-methyl-amino}-propyl)-methyl-amino]-ethylamino}-9-methyl-5,10-diaza-benzo[c]fluoren-7-one | 623924-73-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 3-methoxy-6-{2-[(3-{[2-(3-methoxy-9-methyl-7-oxo-7H-5,10-diaza-benzo[c]fluoren-6-ylamino)-ethyl]-methyl-amino}-propyl)-methyl-amino]-ethylamino}-9-methyl-5,10-diaza-benzo[c]fluoren-7-one
• 英文别名: 5-Methoxy-9-[2-[3-[2-[(5-methoxy-14-methyl-11-oxo-8,15-diazatetracyclo[8.7.0.02,7.012,17]heptadeca-1(10),2(7),3,5,8,12(17),13,15-octaen-9-yl)amino]ethyl-methylamino]propyl-methylamino]ethylamino]-14-methyl-8,15-diazatetracyclo[8.7.0.02,7.012,17]heptadeca-1(10),2(7),3,5,8,12(17),13,15-octaen-11-one
• CAS: 623924-73-2
• 化学式: C₄₃H₄₄N₈O₄
• 分子量: 736.874
• InChiKey: YKSXCIFKPNONRG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.2
• 重原子数：
  55
• 可旋转键数：
  14
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  135
• 氢给体数：
  2
• 氢受体数：
  12

文献信息

• Polycyclic compounds exhibiting anti-tumor activities
  申请人：——

  公开号：US20030229098A1

  公开（公告）日：2003-12-11

  This invention is concerned with novel polycyclic compounds of formula [I], 1 wherein ring A, ring B, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , X, Y, R 1 , R 2′ , R 3′ , R 4′ , R 5′ , R 6 ′, ring A′, ring B′ and X′ are as defined hereinabove as well as pharmaceutically acceptable salts thereof. The compounds have anti-tumor activity and are useful for the treatment of cell proliferative disorders.

  这项发明涉及公式I中的新型多环化合物，其中环A、环B、R1、R2、R3、R4、R5、R6、X、Y、R1、R2'、R3'、R4'、R5'、R6'、环A'、环B'和X'的定义如上所述，以及其药学上可接受的盐。这些化合物具有抗肿瘤活性，可用于治疗细胞增殖性疾病。
• US6946472B2
  申请人：——

  公开号：US6946472B2

  公开（公告）日：2005-09-20
• [EN] DIMERIC POLYCYCLIC COMPOUNDS FOR THE TREATMENT OF TUMORS<br/>[FR] COMPOSES POLYCYCLIQUES DIMERIQUES DESTINES AU TRAITEMENT DES TUMEURS
  申请人：HOFFMANN LA ROCHE

  公开号：WO2003093265A1

  公开（公告）日：2003-11-13

  This invention is concerned with novel polycyclic compounds of the formula (I), wherein ring A, ring B, R1, R2, R3, R4, R5, R6, X, Y, R1', R2', R3', R4', R5', R6', ring A', ring B' and X' are as defined in the claims and description as well as pharmaceutically acceptable salts thereof. The compounds have anti-tumor activity and are useful for the treatment of cell proliferative disorders.